A Phase Ib/II, Open-Label, Multicenter., Randomized, Umbrella Study Evaluating The Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric

Grants and Contracts Details

StatusFinished
Effective start/end date9/28/207/26/23

Funding

  • Genentech Inc: $38,975.00